Ensign Peak Advisors
TGTX icon

Ensign Peak Advisors’s TG Therapeutics TGTX Stock Holding History

Ensign Peak Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$462K Buy
8,417
+400
+5% +$16.4K ﹤0.01% 1014
2026
Q1 		$266K Hold
8,017
– – ﹤0.01% 1174
2025
Q4 		$239K Sell
8,017
-39,490
-83% -$1.29M ﹤0.01% 1222
2025
Q3 		$1.72M Sell
47,507
-260,585
-85% -$8.58M ﹤0.01% 845
2025
Q2 		$11.1M Sell
308,092
-20,900
-6% -$778K 0.02% 446
2025
Q1 		$13M Sell
328,992
-127,025
-28% -$4.27M 0.02% 399
2024
Q4 		$13.7M Hold
456,017
– – 0.02% 392
2024
Q3 		$10.7M Buy
456,017
+385,000
+542% +$8.41M 0.02% 451
2024
Q2 		$1.26M Hold
71,017
– – ﹤0.01% 1137
2024
Q1 		$1.08M Sell
71,017
-11,893
-14% -$189K ﹤0.01% 1265
2023
Q4 		$1.42M Buy
82,910
+4,860
+6% +$56.5K ﹤0.01% 1120
2023
Q3 		$652K Buy
78,050
+27,000
+53% +$376K ﹤0.01% 1486
2023
Q2 		$1.27M Hold
51,050
– – ﹤0.01% 1078
2023
Q1 		$768K Buy
+51,050
New +$775K ﹤0.01% 1445
2022
Q4 		– Sell
-65,580
Closed -$388K – 2188
2022
Q3 		$388K Sell
65,580
-49,850
-43% -$327K ﹤0.01% 1587
2022
Q2 		$491K Buy
115,430
+83,880
+266% +$524K ﹤0.01% 1473
2022
Q1 		$300K Hold
31,550
– – ﹤0.01% 1756
2021
Q4 		$599K Buy
+31,550
New +$819K ﹤0.01% 1554
2021
Q3 		– Sell
-43,703
Closed -$1.7M – 1882
2021
Q2 		$1.7M Hold
43,703
– – ﹤0.01% 1214
2021
Q1 		$2.11M Sell
43,703
-25,606
-37% -$1.23M ﹤0.01% 1093
2020
Q4 		$3.6M Buy
69,309
+1,000
+1% +$33.8K 0.01% 746
2020
Q3 		$1.83M Buy
+68,309
New +$1.57M ﹤0.01% 1016

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Ensign Peak Advisors's TGTX Position: Q2 2026 in Review

Ensign Peak Advisors increased its TG Therapeutics (TGTX) stake by 5% in Q2 2026, buying an estimated $16.4K and bringing the position to 8,417 shares worth $462K. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Ensign Peak Advisors first reported a position in TGTX in Q3 2020 and has held it in 22 quarters since. The position peaked at $13.7M in Q4 2024. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Ensign Peak Advisors held 8,417 shares of TG Therapeutics worth $462K as of Q2 2026.
  • Ensign Peak Advisors bought 400 TG Therapeutics shares in Q2 2026, an estimated $16.4K.
  • TG Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1014 holding.
  • Ensign Peak Advisors first reported a position in TG Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Ensign Peak Advisors's TG Therapeutics position peaked at $13.7M in Q4 2024.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.